Indication Tooltip

LORBRENA® (lorlatinib) is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)

  • that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, and
  • that has spread to other parts of the body, and
  • who have taken the medicine:
    • alectinib, or ceritinib, or
    • both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
  • that is no longer responding to these treatments.

It is not known if LORBRENA is safe and effective in children.

The effectiveness of LORBRENA is based on a study that measured tumor response rate and duration of response. There is an ongoing study to find out how LORBRENA works over a longer period of time.

In a clinical study of 215 patients, LORBRENA was shown to be effective in treating some tumors that had already been treated with certain other medicines for ALK+ NSCLC.

Everyone in the study started on 100-mg LORBRENA tablets once daily.

The study assessed the Overall Response Rate (ORR). This measures tumor response to treatment, including tumor shrinkage, throughout the body or specifically within the brain.

Turn to Pfizer Oncology Together™ to learn about financial assistance resources and get personalized support from one of our dedicated Care Champions.